AcelRx Pharma (ACRX) Misses Q4 EPS by 14c

AcelRx Pharma (NASDAQ: ACRX) reported Q4 EPS of ($0.24), $0.14 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $1.73 million versus the consensus estimate of $4.97 million.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c